Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

manufacturing

Sun to cut jobs in Irish facility closure; Lilly announce further investment in the country

April 6, 2016 Manufacturing and Production, Research and Development Eli Lilly, Ireland, Kinsale, Sun Pharma, cashel, investment, lilly

There was mixed news for pharmaceutical manufacturing in Ireland as Sun Pharma announced its decision to close its facility based …
News
celltrion

Celltrion’s biosimilar for J&J’s arthritis drug gets UF FDA okay

April 6, 2016 Manufacturing and Production, Research and Development

Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson …
News
pfizer_logo

Pfizer to call off $160 billion merger with Allergan

April 6, 2016 Business Services, Research and Development, Sales and Marketing Allergan, Pfizer, deal, legal, merger and acquisition, regulation

US pharma giant Pfizer Inc (NYSE: PFE) has decided to terminate the $160 billion merger with Botox-maker Allergan Plc (NYSE: …
News
trials

Phase III trial initiated in Merck and Pfizer partnership for renal cell carcinoma drug

April 6, 2016 Research and Development Merck, Pfizer, avelumab, carcinoma, inlyta, javelin, partnership, phase III, renal

The first patient has been treated in the Phase III clinical trial, which sees Merck (ETR: MRK) and Pfizer (NYSE: …
News
mr058666-web

Merck receives CE Mark approval for new liquid biopsy test for colorectal cancer

April 6, 2016 Medical Communications, Research and Development, Sales and Marketing CE Mark, Merck, biomarker, biopsy, colorectal cancer, liquid biopsy, ras, sysmex inostics

Merck (ETR: MRK) has announced that their new liquid biopsy RAS biomarker test for metastatic colorectal cancer, developed in collaboration …
News
figures_charts

Valeant’s ad hoc committee closes chapter on Philidor controversy

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Philidor, Valeant, ad hoc, ad hoc committee

Valeant (NYSE: VRX) has announced that the ad hoc committee of the board of directors has finished its review of …
News
pfizerbrussels

Pfizer’s tofacitinib shows promise for psoriatic arthritis treatment in Phase III trial

April 5, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Pfizer, Xeljanz, merger, phase III, psoriatic arthritis, tofacitinib

Pfizer has announced positive top-line results from their latest Phase III study investigating Xeljanz (tofacitinib citrate). The OPAL Broaden trial …
News
samsung

Samsung Bioepis takes AbbVie to court over attempts to delay Humira biosimilars

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Biogen, Humira, Samsung Bioepis, biosimilars, rheumatoid arthritis

Samsung Bioepis has filed a lawsuit against Abbvie (NYSE: ABBV) to stop the maker of the world’s bestselling drug Humira …
News
clinical_trials_2

Flexion Therapeutics announce results for Zilretta trials in osteoarthritis pain

April 5, 2016 Manufacturing and Production, Research and Development drugs, flexion, flexion therapeutics, osteoarthritis, pipeline, treatments, zilretta

Flexion Therapeutics has presented positive results from two pivotal clinical trials for its lead drug candidate, Zilretta, which show that …
News
descovy

FDA approves Gilead’s latest HIV treatment

April 5, 2016 Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …
News
gilead-sciences

Gilead to buy Nimbus Therapeutics’ unit, trial drug for up to $1.2 billion

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Gilead Sciences, M&A, MA, Nimbus Apollo, Nimbus Therapeutics, merger and acquisitions

Gilead Sciences (Nasdaq: GILD) has agreed to buy a unit of biotechnology firm Nimbus Therapeutics and its trial drug to …
News
legal

Janssen and Genmab sued for patent infringement in US

April 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Genmab, Janssen, darzalex, morphosys, patent infringement

German biotech company, Morphosys, is suing Janssen and Genmab for alleged patent infringement in their oncology drug, Darzalex (daratumumab).
News
halaven

Eisai’s Halaven recommended for European approval

April 4, 2016 Research and Development, Sales and Marketing Eisai, Halaven, liposarcoma

Eisai has received a positive opinion from the European Commission’s CHMP for Halaven (eribulin) as a second-line therapy for patients …
News
stocks1

Weekly Movers: Lupin, Natco Pharma, Keryx, Puma Biotech

April 4, 2016 Research and Development, Sales and Marketing

Another week of big gains and some major losses has come to pass. While the Indian pharma sector continues to …
Feature
novartis_window

Research shows Novartis’s Entresto reduces cardiovascular death and heart failure

April 4, 2016 Research and Development, Sales and Marketing Entresto, Novartis, Regeneron, Sanofi, cardiovascular, clinical trial, patent

Novartis has announced results from the PARADIGM-HF clinical trial that show that Entresto (sacubitril/valsartan) consistently demonstrated benefit among heart failure …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026